drugset / Trial / NCT03078855
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Phase 3
Completed
211 enrolled
Jonathan Friedberg
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupQuadruple-blindSupportive care
Summary
Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable outcomes in patients with numerous cancers, there has never been a thorough study of vitamin D treatment in subjects undergoing treatment for cancer. The purpose of this study is to evaluate whether modification of vitamin D levels in the blood, through supplementation, can improve outcomes.
Timeline
- Start
- 2017-09-07
- Primary completion
- 2023-07-21
- Completion
- 2024-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |